Browse research publications from CanRIO members and collaborators advancing the understanding and treatment of rheumatic immune-related adverse events.
Objective Immune checkpoint inhibitors (ICIs) have revolutionized cancer outcomes but are limited by immune-related adverse events (irAEs), including rheumatic irAEs (Rh-irAEs). Aging is associated wi
Introduction Immune checkpoint inhibitors-induced inflammatory arthritis (ICI-IA) affects about 5% of ICI recipients. We aimed (1) to characterize the resolution of ICI-IA during ICI treatment and aft
Objective Another course of immune checkpoint inhibitors (ICIs) is often considered in patients with cancer progression and previous immune-related adverse events, including inflammatory arthritis (IC
Work in progress! Dr. Shahin Jamal and Dr. Tom Appleton are leading a study on Early Adalimumab Induction for Treatment of Steroid-Dependent Checkpoint Inhibitor Associated Inflammatory Arthritis: A P
Coming 2024/2025! With support from the Canadian Rheumatology Association (CRA) Guidelines Committee, CanRIO has assembled a working group of rheumatologists, oncologist and patient representative to
Lourdes Gonzalez Arreola, Jeremiah Tan, Alexandra Ladouceur, Marie Hudson, Carrie Ye, Janet Roberts, Aurore Fifi-Mah, May Choi, Sabrina Hoa, Tom Appleton, Janet Pope, Nancy Maltez, Shahin Jamal on beh
Alexandra Ladouceur, Lourdes Gonzalez Arreola, Shahin Jamal, Marie Hudson, Janet Pope, Sabrina Hoa, Janet Roberts, David Moon, Ammana Karmali, Tatiana Nevskaya, Emma Schmidt1, Nader Toban, Lindsay Cho
Arthritis Care & Research. Vol. 75, No. 2, February 2023, pp 260–271. DOI 10.1002/acr.24784 Abstract: Objective. To determine the risk of recurrent or new malignancy with exposure to targeted disease-
Checking in with Immune Checkpoint Inhibitors: Results from a Needs Assessment Survey of Canadian Rheumatologists
The Effect of Sex on Patients with Pre-existing Rheumatoid Arthritis and Immune Checkpoint Inhibitor-induced Inflammatory Arthritis. Background: Immune checkpoint inhibitors (ICI) are the new pillar o
Title: Utilization of a new educational platform designed to improve the care of cancer patients receiving immunotherapy: An Initiative of CanRIO (Canadian Research Group of Rheumatology in Immuno-Onc
Title: Remitting Seronegative Symmetrical Synovitis with Pitting Edema (RS3PE)-like Syndrome after Immune Checkpoint Inhibition: a CanRIO Study Authors: Azin Rouhi, Shahin Jamal, Marie Hudson, Janet P
Janet Roberts, Kevin Lau, Daniel Ennis, Marie Hudson, Shahin Jamal, Steven Katz, Carrie Ye Title: A web-based education program improves health care provider knowledge for the care of cancer patients
Citation: Kim ST, Chu Y, Misoi M, Suarez-Almazor ME, Tayar JH, Lu H, Buni M, Kramer J, Rodriguez E, Hussain Z, Neelapu SS, Wang J, Shah AY, Tannir NM, Campbell MT, Gibbons DL, Cascone T, Lu C, Blumens
Citation: Sørensen AS, Andersen MN, Juul-Madsen K, Broksø AD, Skejø C, Schmidt H, Vorup-Jensen T, Kragstrup TW. Tumor necrosis factor alpha neutralization attenuates immune checkpoint inhibitor-induce
The Canadian Research Group of Rheumatology in Immuno-Oncology (CanRIO): A nationwide multi-center prospective cohort
Citation: Cunningham-Bussel A, Wang J, Prisco LC, Martin LW, Vanni KMM, Zaccardelli A, Nasrallah M, Gedmintas L, MacFarlane LA, Shadick NA, Awad MM, Rahma O, LeBoeuf NR, Gravallese EM, Sparks JA. Pred
Citation: Chen, A.Y., Wolchok, J.D. & Bass, A.R. TNF in the era of immune checkpoint inhibitors: friend or foe?. Nat Rev Rheumatol 17, 213–223 (2021). Abstract: Immune checkpoint inhibitors (ICIs) are
The Canadian Research Group of Rheumatology in Immuno-Oncology (CanRIO): The Development of a National Collaboration for Research, Advocacy, Education and Optimizing Patient Care in an Emerging and Co
Janet Roberts, Shahin Jamal, Marie Hudson, Aurore Fifi-Mah, Carrie Ye, The Canadian Research group of Rheumatology in Immuno-Oncology (CanRIO) Title: Rheumatic complications of cancer Immunotherapy: A
Ann Rheum Dis 2020 Background: Rheumatic and musculoskeletal immune-related adverse events (irAEs) are observed in about 10% of patients with cancer receiving checkpoint inhibitors (CPIs). Given the r
Citation: van der Kooij MK, Suijkerbuijk KPM, Aarts MJB, et al. Ann Intern Med 2021 February. Online ahead of print There remains hesitancy to treat patients with preexisting autoimmune disease (PAD)
Hoa S, Laaouad L, Roberts J, Ennis D, Ye C, Al Jumaily K, Pope J, Nevskaya T, Saltman A, Himmel M, Rottapel R, Ly C, Colmegna I, Fifi-Mah A, Maltez N, Tisseverasinghe A, Hudson M, Jamal S. Preexisting
Cohen Tervaert JW, Ye C, Yacyshyn E. Adverse Events Associated with Immune Checkpoint Blockade. N Engl J Med. 2018 Mar 22;378(12):1164-5.
Currently recruiting! This is an ongoing prospective, multi-centre, Canadian study looking at clinical phenotypes, outcomes and biomarker profiles of adults with rheumatic immune related adverse event
Machado MAÁ, de Moura CS, Chan K, Curtis JR, Hudson M, Abrahamowicz M, Jamal R, Pilote L, Bernatsky S. Real-world analyses of therapy discontinuation of checkpoint inhibitors in metastatic melanoma pa
Roberts J, Ennis D, Hudson M, Ye C, Saltman A, Himmel M, Rottapel R, Pope J, Hoa S, Tisseverasinghe A, Fifi-Mah A, Maltez N, Jamal S. Rheumatic immune-related adverse events associated with cancer imm
Esfahani K, Elkrief A, Calabrese C, Lapointe R, Hudson M, Routy B, Miller WH Jr, Calabrese L. Moving towards personalized treatments of immune-related adverse events. Nat Rev Clin Oncol. 2020 Aug;17(8
CMAJ 2020 Immune checkpoint inhibitors (ICI's) are increasingly used in cancer immunotherapy, and have shown unprecedented survival benefit in a number of malignancies with historically poor prognoses
Esfahani K, Hudson M, Batist G. Tofacitinib for Refractory Immune-Related Colitis from PD-1 Therapy. N Engl J Med. 2020 Jun 11;382(24):2374-2375.
Acral digital ischemia associated with ICI therapy: A case series of the CANRIO experience
Citation: Braaten TJ, Brahmer JR, Forde PM, et al. Ann Rheum Dis 2020;79:332-338 There remain many unanswered questions in the development and management of immune checkpoint inhibitor-induced inflamm
Pre-existing AID and Immune related adverse events associated with cancer immunotherapy: a case series from CANRIO
Rheumatic immune related adverse events associated with cancer immunotherapy: A nationwide multi-center Canadian cohort from CanRIO
Maltez N, Abdullah A, Fifi-Mah A, Hudson M, Jamal S. Checking in with immune checkpoint inhibitors: Results of a needs assessment survey of Canadian rheumatologists. J Cancer Sci Therap 2019;2(1):12 h
Jamal S, Hudson M, Fifi-Mah A, Ye C. Immune-related Adverse Events Associated with Cancer Immunotherapy: A Review for the Practicing Rheumatologist. J Rheumatol. 2020 Feb;47(2):166-175. http://www.jrh
Roberts J, Smylie M, Walker J, Basappa NS, Chu Q, Kolinsky M, Lyddell C, Ye C. Hydroxychloroquine is a safe and effective steroid-sparing agent for immune checkpoint inhibitor-induced inflammatory art
Ye C, Jamal S, Hudson M, Fifi-Mah A, Roberts J. Immune Checkpoint Inhibitor Associated Rheumatic Adverse Events: a Review of Their Presentations and Treatments. Curr Treat Options in Rheum. 2019 (5):2
Roberts JH, Smylie M, Oswald A, Cusnir I, Ye C. Hepatitis is the new myositis: immune checkpoint inhibitor-induced myositis. Melanoma Res. 2018 Oct;28(5):484-485.
Esfahani K, Meti N, Miller WH Jr, Hudson M. Adverse events associated with immune checkpoint inhibitor treatment for cancer. CMAJ. 2019 Jan 14;191(2):E40-E46.
Ye C, Jamal S, Hudson M. CRAJ 2018: http://craj.ca/archives/2018/English/Fall/Ye.php
Note: Publication filtering is client-side. Links will be updated to point directly to PubMed entries. Additional tags (guidelines, case series, cohort, reviews) to be added per meeting discussion.